

KONSTANTINOS POULAS

ASSOCIATE PROFESSOR
LABORATORY OF MOLECULAR BIOLOGY AND IMMUNOLOGY
DEPARTMENT OF PHARMACY, UNIVERSITY OF PATRAS

PROFESSIONAL AND SCIENTIFIC ACTIVITY

«C.V.»

FEBRUARY 2020
PATRAS

PERSONAL DETAILS

SURNAME: POULAS
NAME: KONSTANTINOS
DATE OF BIRTH: 29 JANUARY 1970
PLACE OF BIRTH: CHAIDARI, ATHENS, GREECE
NATIONALITY: GREEK
SEX: MALE
WORK ADDRESS: UNIVERSITY OF PATRAS, DEPARTMENT OF PHARMACY,
RIO, PATRAS, GREECE
TELEPHONE: OFFICE: +30 2610 962353
LABORATORY: +30 2610 962354
MOBILE: +30 6937 333722
E-MAIL ADDRESS: kpoulas@upatras.gr

ACADEMIC POSITIONS:

9/2014 – Today: Associate Professor of Biochemistry, Department of Pharmacy, University of Patras

12/2009 – 9/2014: Assistant Professor of Biochemistry, Department of Pharmacy, University of Patras

8/2003 – 12/2009: Lecturer of Biochemistry, Department of Pharmacy, University of Patras

2001 – 8/2003: Postdoctoral Researcher, Department of Biochemistry, Hellenic Pasteur Institute.

EDUCATION:

1994 - 2001: PhD in Biochemistry, School of Biology, Kapodistrian University of Athens, Athens, GREECE. The experimental part of the PhD was performed in Hellenic Pasteur Institute, under the supervision of Prof. S. Tzartos.

1993: BSc in Biology, School of Biology, Kapodistrian University of Athens, Athens, GREECE.

RESEARCH INTERESTS

- Cloning, expression, purification and biochemical characterization of recombinant proteins – PROTEIN REPAIR innovative method.
- Toxicological and preclinical studies on non-combustible products: e-cigs and HnB products
- Structural studies of proteins by X-ray crystallography and molecular modelling. Innovative crystallization methods.
- Innovative technology NCCT (Non-contact Current Transfer) for wound/burns healing. Studies at cellular and molecular level.
- Databases for autoimmune and genetic diseases.

PUBLICATIONS IN PEER-REVIEWED JOURNALS

2020

A89 El Mubarak MA, Danika C, Cachon C, Korovila C, Atsopardi K, Panagopoulos N, Margarity M, **Poulas K**, Sivolapenko GB. In vivo quantification and pharmacokinetic studies of cotinine in mice after smoke exposure by LC-MS/MS. *Biomed Chromatogr.* 2020 Feb;34(2):e4752.

2019

A88 Isik Andrikopoulos G, Farsalinos K, **Poulas K**. Electronic Nicotine Delivery Systems (ENDS) and Their Relevance in Oral Health. *Toxics.* 2019 Dec 6;7(4). pii: E61. doi: 10.3390/toxics7040061. Review.

A87 Lagoumintzis G, Zagoriti Z, Jensen MS, Argyrakos T, Koutsojannis C, **Poulas K**. Wireless Direct Microampere Current in Wound Healing: Clinical and Immunohistological Data from Two Single Case Reports. *Biosensors (Basel).* 2019 Sep 5;9(3).

A86 Lamos S, Kostenidou E, Farsalinos K, Zagoriti Z, Ntoukas A, Dalamarinis K, Savranakis P, Lagoumintzis G, **Poulas K**. Real-Time Assessment of E-Cigarettes and Conventional Cigarettes Emissions: Aerosol Size Distributions, Mass and Number Concentrations. *Toxics.* 2019 Aug 30;7(3).

A85. Farsalinos K, Siakas G, **Poulas K**, Voudris V, Merakou K, Barbouni A. E-cigarette use is strongly associated with recent smoking cessation: an analysis of a representative population sample in Greece. *Intern Emerg Med.* 2019 Jan 14.

A84 Wirsing P, Konstantakaki M, **Poulas K**. Martorell's ulcer successfully treated by Wireless Microcurrent Stimulation technology. *Advances in Skin and Wound Care.* 2019 Feb; 32(2) 81-84.

2018

A83 Farsalinos K, Yannovits N, Sarri T, Voudris V, **Poulas K**, Leischow S. Carbonyl emissions from a novel heated tobacco product (IQOS): comparison with an e-cigarette and a tobacco cigarette. *Addiction.* 2018 Nov. 113(11): 2099-2106.

A82 Kouretas D, Tsatsakis A, **Poulas K**. Editorial: Alternative tobacco products: Toxicology and health issues. *Food Chem Toxicol.* 2018 May 26. pii: S0278-6915(18)30356-9.

A81 Konstantinou E, Fotopoulou F, Drosos A, Dimakopoulou N, Zagoriti Z, Niarchos A, Makrynioti D, Kouretas D, Farsalinos K, Lagoumintzis G, **Poulas K**. Tobacco-specific nitrosamines: A literature review. *Food Chem Toxicol.* 8;118:198-203.

A80 Farsalinos KE, Siakas G, **Poulas K**, Voudris V, Merakou K, Barbouni A. Electronic cigarette use in Greece: an analysis of a representative population sample in Attica prefecture. *Harm reduction journal.* 13;15(1):20.

A79 Zagoriti Z, Lagoumintzis G, Perroni G, Papathanasiou G, Papadakis A, ... **Poulas K**. Evidence for association of STAT4 and IL12RB2 variants with Myasthenia gravis susceptibility: What is the effect on gene expression in thymus? *Journal of Neuroimmunology*. 319, 93-99.

A78 Kamilari E, Farsalinos K, **Poulas K**, Kontoyannis CG, Orkoula M. Detection and quantitative determination of heavy metals in electronic cigarette refill liquids using Total Reflection X-ray Fluorescence Spectrometry. *Food and Chemical Toxicology*. 116(Pt B):233-237

A77 El Mubarak M, Danika C, Vlachos N, Farsalinos K, **Poulas K**, Sivolapenko G. Development and validation of analytical methodology for the quantification of aldehydes in e-cigarette aerosols using UHPLC-UV. *Food and Chemical Toxicology*. 116(Pt B):147-151

2017

A76 Farsalinos KE, **Poulas K**, Voudris V. Changes in puffing topography and nicotine consumption depending on the power setting of electronic cigarettes. *Nicotine and Tobacco Research*. (Impact factor: 4.6 - Citations:) 2018 Jul 9; 20(8): 993-997.

A75 Niarchos A, Lagoumintzis G, **Poulas K**. TA-GC cloning: a new simple and versatile technique for the directional cloning of PCR products for recombinant protein expression *PLoS One*. 12(11), e0186568

A74 Hatzis Y, Thireou T, Viennas E, Atlamazoglou V, Papadopoulos G, **Poulas K**, Eliopoulos E, Tzimas J. RGDtrip: A Database for the Investigation of Proteins Containing the RGD Tripeptide. *Current Bioinformatics*. In press

A73 Farsalinos KE, Voudris V, Spyrou A, **Poulas K**. E-cigarettes emit very high formaldehyde levels only in conditions that are aversive to users: A replication study under verified realistic use conditions. *Food Chem Toxicol*. 109:90-94.

A72 Farsalinos KE, Yannovits N, Sarri T, Voudris V, **Poulas K**. Nicotine delivery to the aerosol of a heat-not-burn tobacco product: comparison with a tobacco cigarette and e-cigarettes. *Nicotine Tob Res*. 2017 Jun 16. doi: 10.1093/ntr/ntx138.

A71 Farsalinos KE, **Poulas K**, Voudris V, Le Houezec J. Prevalence and correlates of current daily use of electronic cigarettes in the European Union: analysis of the 2014 Eurobarometer survey. *Intern Emerg Med*. 12(6), 757-763.

A70 Farsalinos KE, **Poulas K**, Voudris V, Le Houezec J. E-cigarette use in the European Union: millions of smokers claim e-cigarettes helped them quit. *Addiction*. 2017 Mar;112(3):545-546.

2016

A69 Balasopoulou A, Stanković B, Panagiotara A, Nikčević G, Peters BA, John A, Mendrinou E, Stratopoulos A, Legaki AI, Stathakopoulou V, Tsolia A, Govaris N, Govari S, Zagoriti Z, **Poulas K**, Kanariou M, Constantinidou N, Krini M, Spanou K, Radlovic N, Ali BR, Borg J, Drmanac R, Chrousos G, Pavlovic S, Roma E, Zukic B, Patrinos GP, Katsila T. Novel genetic risk variants for pediatric celiac disease. *Hum Genomics*. 24;10(1):34.

A68 Jelastopulu E, Fafliora E, Plota A, Babalis V, Bartsokas C, **Poulas K**, Plotas P. Knowledge, behaviours and attitudes regarding HPV infection and its prevention in female students in West Greece. *Eur Rev Med Pharmacol Sci.* 20(12):2622-9.

A67 Farsalinos KE, **Poulas K**, Voudris V, Le Houezec J. Electronic cigarette use in the European Union: analysis of a representative sample of 27 460 Europeans from 28 countries. *Addiction.* 111(11):2032-2040.

A66 Farsalinos KE, Yannovits N, Sarri T, Voudris V, **Poulas K**. Protocol proposal for, and evaluation of, consistency in nicotine delivery from the liquid to the aerosol of electronic cigarettes atomizers: regulatory implications. *Addiction.* 111(6):1069-76.

2015

A65 Niarchos A, Lagoumintzis G, **Poulas K**. Utilizing the virus-induced blocking of apoptosis in an easy baculovirus titration method. *Sci Rep.* 5:15487.

A64 Farsalinos KE, Gillman G, **Poulas K**, Voudris V. Tobacco-Specific Nitrosamines in Electronic Cigarettes: Comparison between Liquid and Aerosol Levels. *Int J Environ Res Public Health.* 12(8):9046-53.

A63 Farsalinos KE, Spyrou A, Stefanopoulos C, Tsimopoulou K, Kourkouveli P, Tsiapras D, Kyrzopoulos S, **Poulas K**, Voudris V. Nicotine absorption from electronic cigarette use: comparison between experienced consumers (vapers) and naïve users (smokers). *Sci Rep.* 5:11269. doi: 10.1038/srep11269.

A62 Farsalinos KE, Voudris V, **Poulas K**. E-cigarettes generate high levels of aldehydes only in 'dry puff' conditions. *Addiction.* 110(8):1352-6

A61 Farsalinos KE, Voudris V, **Poulas K**. Are metals emitted from electronic cigarettes a reason for health concern? A risk-assessment analysis of currently available literature. *Int J Environ Res Public Health.* 12(5):5215-32.

A60 Yilmaz V, Oflazer P, Aysal F, Durmus H, **Poulas K**, Yentur SP, Gulsen-Parman Y, Tzartos S, Marx A, Tuzun E, Deymeer F, Saruhan-Direskeneli G. Differential Cytokine Changes in Patients with Myasthenia Gravis with Antibodies against AChR and MuSK. *PLoS One.* 10(4):e0123546.

A59 Farsalinos KE, Gillman IG, Melvin MS, Paolantonio AR, Gardow WJ, Humphries KE, Brown SE, **Poulas K**, Voudris V. Nicotine levels and presence of selected tobacco-derived toxins in tobacco flavoured electronic cigarette refill liquids. *Int J Environ Res Public Health.* 12(4):3439-52.

2014

A58 Boltsis I, Lagoumintzis G, Chatzileontiadou D, Giastas P, Tzartos SJ, Leonidas D, **Poulas K**. Non-contact Current Transfer Induces the Formation and Improves the X-ray Diffraction Quality of Protein Crystals *Cryst. Growth Des.*, 2014, 14 (9), pp 4347–4354

A57 Kambouris M, Zagoriti Z, Lagoumintzis G, **Poulas K**. From therapeutic Electrotherapy to Electroceuticals: Formats, Applications and Prospects of Electrostimulation. *Annual Research & Review in Biology*, ISSN: 2347-565X, Vol.: 4, Issue.: 20 (16-31 October)

A56 Michail G, Smaili M, Vozikis A, Jelastopulu E, Adonakis G, **Poulas K**. Female students receiving post-secondary education in Greece: the results of a collaborative human papillomavirus knowledge survey. *Public Health*. 128(12):1099-105.

A55 Avidan N, Le Panse R, Harbo HF, Bernasconi P, **Poulas K**, Ginzburg E, Cavalcante P, Colleoni L, Baggi F, Antozzi C, Truffault F, Horn-Saban S, Pöschel S, Zagoriti Z, Maniaol A, Lie BA, Bernard I, Saoudi A, Illes Z, Casasnovas Pons C, Melms A, Tzartos S, Willcox N, Kostera-Pruszczyk A, Tallaksen C, Mantegazza R, Berrih-Aknin S, Miller A. VAV1 and BAFF, via NF κ B pathway, are genetic risk factors for myasthenia gravis. *Ann Clin Transl Neurol*. 1(5):329-39.

A54 Gkantouna VA, Kambouris ME, Viennas ES, Ioannou ZM, Paraskevas M, Lagoumintzis G, Zagoriti Z, Patrinos GP, Tzimas GE, **Poulas K**. Introducing dAUTObase: a first step towards the global scale geoepidemiology of autoimmune syndromes and diseases. *Bioinformatics*. 31(4):581-6.

A53 Kordas G, Lagoumintzis G, Sideris S, **Poulas K**, Tzartos SJ. Direct proof of the in vivo pathogenic role of the AChR autoantibodies from myasthenia gravis patients. *PLoS One*. 9(9):e108327.

A52 Dalabira E, Viennas E, Daki E, Komianou A, Bartsakoulia M, **Poulas K**, Katsila T, Tzimas G, Patrinos GP. DruGeVar: an online resource triangulating drugs with genes and genomic biomarkers for clinical pharmacogenomics. *Public Health Genomics*. 17(5-6):265-71.

A51 Kouvatsos N, Niarchos A, Zisimopoulou P, Eliopoulos E, **Poulas K**, Tzartos S. Purification and functional characterization of a truncated human $\alpha 4\beta 2$ nicotinic acetylcholine receptor. *Int J Biol Macromol*. 70:320-6.

A50 Ulusoy C, Kim E, Tüzün E, Huda R, Yılmaz V, **Poulas K**, Trakas N, Skriapa L, Niarchos A, Strait RT, Finkelman FD, Turan S, Zisimopoulou P, Tzartos S, Saruhan-Direskeneli G, Christadoss P. Preferential production of IgG1, IL-4 and IL-10 in MuSK-immunized mice. *Clin Immunol*. 151(2):155-63.

2013

A49 Lagoumintzis G, Zisimopoulou P, Trakas N, Grapsa E, **Poulas K**, Tzartos SJ. Scale up and safety parameters of antigen specific immunoadsorption of human anti-acetylcholine receptor antibodies. *J Neuroimmunol*. 15;267(1-2):1-6.

A48 Niarchos A, Zouridakis M, Douris V, Georgostathi A, Kalamida D, Sotiriadis A, **Poulas K**, Iatrou K, Tzartos SJ. Expression of a highly antigenic and native-like folded extracellular domain of the human $\alpha 1$ subunit of muscle nicotinic acetylcholine receptor, suitable for use in antigen specific therapies for Myasthenia Gravis. *PLoS One*. 8(12):e84791.

A47 Zagoriti Z, Kambouris ME, Patrinos GP, Tzartos SJ, **Poulas K**. Recent advances in genetic predisposition of myasthenia gravis. *Biomed Res Int*. 2013;404053.

A46 Papadopoulos P, Viennas E, Gkantouna V, Pavlidis C, Bartsakoulia M, Ioannou ZM, Ratbi I, Sefiani A, Tsaknakis J, **Poulas K**, Tzimas G, Patrinos GP. Developments in FINDbase worldwide database for clinically relevant genomic variation allele frequencies. *Nucleic Acids Res*. 2014 Jan;42(Database issue):D1020-6.

A45 Tafrali C, Paizi A, Borg J, Radmilovic M, Bartsakoulia M, Giannopoulou E, Giannakopoulou O, Stojiljkovic-Petrovic M, Zukic B, **Poulas K**, Stavrou EF, Lambropoulou P, Kourakli A, Felice AE, Papachatzopoulou A, Philipsen S, Pavlovic S, Georgitsi M, Patrinos GP. (2013). Genomic variation in the MAP3K5 gene is associated with β -thalassemia disease severity and hydroxyurea treatment efficacy, *Pharmacogenomics*; 14(5):469-83.

A44. Castana O, Dimitrouli A, Argyrakos T, Theodorakopoulou E, Stampolidis N, Papadopoulos E, Pallantzas A, Stasinopoulos I and **Poulas K**. (2013). Wireless Electrical Stimulation: An Innovative Powerful Tool for the Treatment of a Complicated Chronic Ulcer, *The International Journal of Lower Extremity Wounds*; 12:18-21.

A43. Ramadhinara A, **Poulas K**. (2013). Use of wireless microcurrent stimulation for the treatment of diabetes-related wounds: 2 case reports, *Adv Skin Wound Care*; 26(1):1-4.

A42. Kambouris M, Velegaki A, Patrinos GP, Poulas K. Biosecurity threats about the combination of aerobiology, morphology and genetic manipulation of fungal spores. *Journal of life sciences*. 7(2), 131.

2012

A41. Lazaridis K, Zisimopoulou P, Lagoumintzis G, Skriapa L, Trakas N, Evangelakou P, Kanelopoulos I, Grapsa E, **Poulas K**, Tzartos S. (2012). Antigen-specific apheresis of autoantibodies in myasthenia gravis, *Ann N Y Acad Sci*; 1275(1):7-12.

A40 Giannopoulou E, Bartsakoulia M, Tafrali C, Kourakli A, **Poulas K**, Stavrou EF, Papachatzopoulou A, Georgitsi M, Patrinos GP. (2012). A single nucleotide polymorphism in the HBBP1 gene in the human β -globin locus is associated with a mild β -thalassemia disease phenotype, *Hemoglobin*; 36(5):433-45.

A39 Zagoriti Z, Georgitsi M, Giannakopoulou O, Ntellos F, Tzartos SJ, Patrinos GP, **Poulas K**. (2012). Genetics of myasthenia gravis: a case-control association study in the Hellenic population, *Clin Dev Immunol*; 48:491-9.

A38 **Poulas K**, Katsouraki E, Kordas G, Kokla A, Tzartos SJ*. (2012). Anti-MuSK- and anti-AChR-positive myasthenia gravis induced by D-penicillamine, *Journal of Neuroimmunology*; 250(1-2):94-8

A37 Viennas E, Gkantouna V, Ioannou M, Georgitsi M, Rigou M, **Poulas K**, Patrinos GP, Tzimas GE. (2012). Population-Ethnic Group Specific Genome Variation Allele Frequency Data: A Querying and Visualization Journey, *Genomics*; 100:93-101

A36 Haidinis V, Dalkas G, **Poulas K**, Spyroulias G (2012) Molecular Modeling and Conformational Analysis of MuSK Protein. *AIAI* (2) 2012: 642-650

A35 Gkantouna V, Ioannou ZM, Tsakalidis A, Viennas E, **Poulas K**, Tsaknakis J, Tzimas J. (2012). Towards an era of epidemiological databases for autoimmune diseases. *BIBE* 2012: 69-73

2011

A34 Pavlidis C, Karamitri A, Barakou A, Cooper DN, **Poulas K**, Topouzis S & Patrinos GP. (2011). Ascertainment and critical assessment of the views of the general public and healthcare professionals on nutrigenomics in Greece, *Personalized Medicine*; 9(2):201-10.

A33 Dimitropoulos N, Papakyriakou A, Dalkas G, Chasapis C, **Poulas K** and Spyroulias G. (2011). A computational investigation on the role of glycosylation in the binding of alpha1 nicotinic acetylcholine receptor with two alpha-neurotoxins. *Proteins*; 79:142-152.

A32 Sagia A, Cooper DN, **Poulas K**, Stathakopoulos V, Patrinos GP. (2011). Critical appraisal of the private genetic and pharmacogenomic testing environment in Greece. *Personalized Medicine*; 8(4):413-420.

A31 Mai Y, Koromila T, Sagia A, Cooper DN, Vlachopoulos G, Lagoumintzis G, Kollia P, **Poulas K**, Stathakopoulos V, Patrinos GP. (2011). A critical view of the general public's awareness and physicians' opinion of the trends and potential pitfalls of genetic testing in Greece, *Personalized Medicine*; 8(5):551-61

2010

A30 Georgitsi M, Viennas E, Gkantouna V, Christodouloupoulou E, Zagoriti Z, Tafrali C, Ntellos F, Giannakopoulou O, Boulakou A, Vlahopoulou P, Kyriacou E, Tsaknakis J, Tsakalidis A, **Poulas K**, Tzimas G, Patrinos GP. (2010). Population-specific documentation of pharmacogenomic markers allelic frequencies in the Frequency of INherited Disorders database. *Pharmacogenomics*; 12(1):49-58.

A29 Georgitsi M, Viennas E, Gkantouna V, van Baal S, Petricoin EF, **Poulas K**, Tzimas G, Patrinos GP. (2010). FINDbase: A worldwide database for genetic variation allele frequencies updated, *Nucleic Acids Research*; 39(Database issue):D926-32

A28 van Baal S, Zlotogora J, Lagoumintzis G, Gkantouna V, Tzimas I, **Poulas K**, Tsakalidis A, Romeo G, Patrinos GP. (2010). ETHNOS: A versatile electronic tool for the development and curation of national genetic databases, *Hum Genomics*; 4(5):361-8.

A27 Lagoumintzis G, **Poulas K**, Patrinos GP. (2010). Genetic databases and their potential in pharmacogenomics, *Curr Pharm Des*; 16(20):2224-31.

A26 Lagoumintzis G, Zisimopoulou P, Kordas G, Lazaridis K, **Poulas K**, Tzartos SJ. (2010). Recent approaches to the development of antigen-specific immunotherapies for myasthenia gravis, *Autoimmunity*; 43(5-6):436-45.

A25 Antoniou DI, Georgitsi M.A, Gkantouna V.A, Patrinos G.P, **Poulas K**, Tsakalidis AK, Tzimas G.E, Viennas E.S. (2010). dAUTObase: Mining gems on autoimmune diseases utilizing web visualization technologies *ITAB 2010*, 1-5

2009

A24 Tsiamalos P, Kordas G, Kokla A, **Poulas K**, Tzartos SJ. (2009). Epidemiological and immunological profile of MuSK Myasthenia gravis in Greece, *European Journal of Neurology*; 16:925-30.

A23 Zouridakis M, Zisimopoulou P, Eliopoulos E, **Poulas K**, Tzartos SJ. (2009). Design and expression of human $\alpha 7$ nicotinic acetylcholine receptor extracellular domain mutants with enhanced solubility and ligand-binding properties. *Biochim Biophys Acta*; 1794:355-66.

A22 Zouridakis M, Zisimopoulou P, **Poulas K**, Tzartos SJ. (2009). Recent advances in understanding the structure of nicotinic acetylcholine receptors, *IUBMB Life*; 61:407-23.

2008

A21 Bitzopoulou K, Kostelidou K, **Poulas K**, Tzartos SJ. (2008). Mutant forms of the extracellular domain of the human acetylcholine receptor gamma-subunit with improved solubility and enhanced antigenicity. The importance of the Cys-loop, *BBA - Proteins and Proteomics*; 1784:1226-33.

A20 Tzartos SJ, Bitzopoulou K, Gavra I, Kordas G, Jacobson L, Kostelidou K, Lagoumintzis G, Lazos O, **Poulas K**, Sideris S, Sotiriadis A, Trakas N, Zisimopoulou P. (2008). Antigen-specific apheresis of pathogenic autoantibodies from myasthenia gravis sera, *Ann. N.Y Acad. Sci*; 1132:291-9.

A19 Zisimopoulou P, Lagoumintzis G, **Poulas K**, Tzartos SJ. (2008). Antigen specific apheresis of human anti-acetylcholine receptor autoantibodies from myasthenia gravis patients' sera using *Escherichia coli*-expressed receptor domains. *J. Neuroimmunol*; 200:133-41 (IF 2,9 – 3)

A18 Zisimopoulou P, Lagoumintzis G, Kostelidou K, Bitzopoulou K, Kordas G, Trakas N, **Poulas K**, Tzartos SJ. (2008). Towards antigen-specific apheresis of pathogenic autoantibodies from myasthenic patients as a further step to plasmapheresis treatment. *J. Neuroimmunol*; 201-202:95-103.

A17 Konstantakaki M, Tzartos SJ, **Poulas K**, and Eliopoulos E. (2008). Model of the extracellular domain of the human alpha7 nAChR based on the crystal structure of the mouse alpha 1 nAChR extracellular domain; *Journal of Molecular Graphics and Modelling*, 26, 1333-37.

2007

A16 Kalamida D, **Poulas K**, Avramopoulou V, Fostieri E, Lagoumintzis G, Lazaridis K, Sideri A and Tzartos S. (2007). Muscle and Neuronal Nicotinic Acetylcholine Receptors: Structure, Function and Pathogenicity. *FEBS Journal*, 274 3799–3845.

A15 Zouridakis M, Zisimopoulou P, Eliopoulos E, Jacobson L, **Poulas K** and Tzartos SJ. (2007). Recombinant extracellular domains of human neuronal nicotinic receptors: Preliminary studies on mutant forms for the improvement of solubility. *Neurophysiology*, 39(4/5): 259-63.

A14 Sideris S, Lagoumintzis G, Kordas G, Kostelidou K, Sotiriadis A, **Poulas K** and Tzartos SJ. (2007). Isolation and functional characterization of anti-acetylcholine receptor subunit-specific autoantibodies from myasthenic patients: receptor loss in cell culture, *J. Neuroimmunol*; 189:111-7.

A13. Zouridakis M, Kostelidou K, Sotiriadis A, Stergiou C, Eliopoulos E, **Poulas K** and Tzartos S. (2007). Circular Dichroism Studies of Recombinant Extracellular Domains of Human Muscle and Neuronal Nicotinic Acetylcholine Receptors Provide an Insight into their structure. *Intl. J. Biol. Macromol*; 41:423-9.

A12. Konstantakaki M, Tzartos SJ, **Poulas K**, and Eliopoulos E. (2007). Molecular modeling of the complex between Torpedo acetylcholine receptor and anti-MIR Fab198. *Biochem. Biophys. Res. Commun*; 356:569-75.

1998-2006

A11 Fostieri E, Kostelidou K, **Poulas K** and Tzartos SJ. (2006). Recent advances in the understanding and therapy of myasthenia gravis, *Future Neurology*; 1(5), 799-817.

A10 Tataridis D, Kolocouris A, Fytas G, Kolocouris N, Foscolos GB, **Poulas K** and Tzartos SJ. (2002). Mounting the nicotinic pharmacophoric structural elements in an homoadamantane scaffold: Synthesis, molecular modeling and binding affinities to $\alpha 7$ nicotinic acetylcholine receptors, *Il Farmaco*; 57, 979-84.

A9 Campos E, Schiavi C, Bolognesi A, Lubelli C, Polito L, Bellusci C, Vismara S, **Poulas K**, Tzartos SJ and Stirpe F. (2002). Selective lesions of rabbit extraocular muscles injected with the anti-AChR immunotoxin saporin-mAb73, *Current Eye Research*; 24(1):58-65.

A8. **Poulas K**, Eliopoulos E, Vatzaki E, Navaza J, Kontou M, Oikonomakos N, Acharya KR and Tzartos SJ. (2001). Crystal structure of Fab198, an efficient protector of acetylcholine receptor against myasthenogenic antibodies, *European Journal of Biochemistry*; 268, 3685-3693.

A7 **Poulas K**, Tsibri E, Kokla A, Papanastasiou D, Tsouloufis T, Marinou M, Tsantili P, Papapetropoulos T and Tzartos SJ. (2001). Epidemiology of seropositive myasthenia gravis in Greece, *Journal of Neurology, Neurosurgery and Psychiatry*; 71(3) :352-356.

A6 **Poulas K** and Tzartos SJ. (2001). The 'gender gap' in autoimmune diseases, *The Lancet*; 357(9251):234.

A5 **Poulas K**, Tsibri E, Papanastasiou D, Tsouloufis T, Marinou M, Tsantili P, Papapetropoulos T and Tzartos SJ. (2000). Equal male and female incidence of myasthenia gravis; *Neurology*, 54(5):1202-1203.

A4 Papanastasiou D, **Poulas K**, Kokla A and Tzartos SJ. (2000). Prevention of passively transferred experimental autoimmune myasthenia gravis by fragments of monoclonal antibodies directed against the main immunogenic region of the acetylcholine receptor, *J. Neuroimmunol*; 104(2):124-132.

A3 **Poulas K**, Tsouloufis T and Tzartos SJ. (2000). Treatment of passively transferred experimental autoimmune myasthenia gravis using papain, *Clinical and Experimental Immunology*; 120:363-368.

A2 Papanastasiou D, Mamalaki A, Eliopoulos E, **Poulas K**, Liolitsas C and Tzartos SJ. (1999). Construction and characterization of a humanized single chain Fv antibody fragment against the main immunogenic region of the acetylcholine receptor, *J. Neuroimmunol*; 94:182-195.

A1 De La Porte S, Chaubourt E, Fabre F, **Poulas K**, Chapron J, Eymard B, Tzartos SJ and Koenig J. (1998). Accumulation of acetylcholine receptor is a necessary condition for normal accumulation of acetylcholinesterase during in vitro neuromuscular synaptogenesis, *European Journal of Neuroscience*; 10:1631-1643.

TOTAL IMPACT FACTOR ~ 300

TOTAL CITATIONS > 2500

h-index = 25

First Author = 6

Last Author = 14

Corresponding Author = 25

PUBLICATIONS IN GREEK JOURNALS

Kyriazis I, Kambouris M, **Poulas K**, Patrinos G. Molecular techniques for the detection and characterization of microorganisms. *Archives of Hellenic Medicine / Arheia Ellenikes Iatrikes* . Jan/Feb2014, Vol. 31 Issue 1, p23-40. 18p.

Eliopoulos GZ, Poulas K, Patrinos P, Kambouris M. Ancient Greek Medicine. *Archives of Hellenic Medicine*, 30(5), 619-626, 2013

Toubouli E, Kambouris M, Patrinos G, Vozikis A & **Poulas K**. (2012) Corporate Social Responsibility in Greek pharmaceutical companies. *e-JST*, 5(7) 43-57

Lagoumintzis G, Poulas K, Tzartos SJ. (2006). Myasthenia gravis. *Axon*, 9(1), 6-15.

Tzartos S, Gavra I, Kostelidou K, Lazos O, **Poulas K**, Sideris S, Sotiriadis S and Trakas N. (2005) Myasthenia gravis. Pathogenesis and antigen-specific therapeutic approaches. *BIO* Jul-Sept, 34.

Lafgoumintzis G, Kordas G, Poulas K (2005). Muscular Dystrophy. *Ergotherapy*, 24, 12-16.

Poulas K, Margeti M and Tzartos J (2004). Myasthenia: A prototype autoimmune disease. *Ergotherapy*, 19: 23-27

Papanastasiou D, Mamalaki A, Poulas K, Eliopoulos E, Tzartos S (1998) Myasthenia gravis: Humanization of a monoclonal antibody and protection of the acetylcholine receptor. *Archives of Hellenic Medicine*, 15(4):356-363.

PARTICIPATION IN SPECIAL EDITIONS

Zisimopoulou, P., Lagoumintzis, G., Trakas, N., Giastas, P., **Poulas, K.** and *Tzartos, S.J.* (2009) Antigen-specific apheresis of autoantibodies as a treatment strategy for myasthenia gravis. In book: *Myasthenia Gravis: Disease Mechanisms and Immune Intervention*. 2nd edition. Edited by P. Christadoss. Linus Publications, NY. pp. 393--406

Tzartos, S.J., *Cung, M.T.*, *Eliopoulos, E.*, *Mamalaki, A.*, *Marraud, M.*, *Papanastasiou, D.*, **Poulas, K.**, *Sakarellos, C.*, *Sakarellos-Daitsiotis, M.*, *Tsikaris, V.*, and *Tsouloufis, T.* (2000). Synthetic peptides and recombinant polypeptides in the study of the nicotinic acetylcholine receptor and myasthenia gravis. *Proc. 2nd Hellenic Forum on Bioactive Peptides, Patras.* pp. 165-176

Poulas K, *Zagoriti Z,* *Kambouris M* and *Lagoumintzis G.* *Advanced Genetics in Myasthenia Gravis.* In book: *Novel challenges in myasthenia gravis,* Edited by Nova publications. pp 109-132

Paxinou E, *Lagoumintzis G,* *Zagoriti Z,* *Niarchos A,* *Boltsis I,* **Poulas K.** *Leg Ulcer and Chronic Wounds: Innovative Healing Methods.* In book: *Leg Ulcers and Chronic Wounds.* Edited by Nova publications. pp 1-21

BOOKS

Translation and Editing «GENES AND DNA», (Savallas ed.)

Translation and Editing «Essentials of Clinical Immunology», (Parisianou ed.)

Poulas K. and Sideris S. *Laboratory Methods for Protein Analysis,* Kallipos, 2015

Proteins: Structure, function, sequencing and characterization. (Hellenic Open University)

Translation and Editing «Biochemistry» (R. Ochs), (Parisianou ed) (Together with Prof. Leonidas)

«Cosmetics», TO ΔONTI ed.

REVIEWER

- Reviewer for International Journals, like:

Lancet Neurology,

PLOS One,

Environmental Research,

Journal of Hazardous Materials,
Scientific reports,
Journal of Clinical Laboratory Analysis,
Environmental Pollution,
Case Reports in Emergency Medicine,
The International Journal of Neuroscience,
International Wound Journal,
Journal of Pharmacy and Pharmacology,
International Journal of Environmental Research and Public Health,
Journal of Neuroimmunology,
Microchemical Journal,
Journal of Case Reports and Studies (JCRS),
Journal of the Neurological Sciences, HEALTH,
Open Journal of Applied Science,
Global Health Research and Policy,
Journal of Biosciences and Medicines,
Molecules,
Int J. on Artificial Intelligence Tools (IJAIT)

- Guest Editor, "Food and Chemical Toxicology"

- Reviewer for GSRT, ELIDEK, IKY e.t.c.

- Reviewer for: EU, Cancer Research UK e.t.c.

TEACHING

Supervisor of one Academic University Fellowship (P. Plotas)
Supervisor of three postdoctoral researchers (Lagoumintzis G, Kalamida D, Sideri A)
Supervisor of 2 finished PhD students, while 5 more are in progress
Supervisor of more than 40 postgraduate students
Participation in more than 15 PhD advisory and examining committees
Participation in more than 30 postgraduate advisory committees

More than 60 diploma students have been trained in our lab under my supervision (Departments Pharmacy, Biology, Chemistry)

2003 – Today: Teaching Biochemistry I and II, Immunology and Microbiology in Department of Pharmacy, University of Patras

2003 – Today: Teaching Proteins Biochemistry, Bioanalysis, Bioinformatics, Molecular Diagnosis, in Department of Pharmacy, University of Patras, Postgraduate studies

2003 – Today: Participation in various postgraduate courses in "Medicinal Chemistry", "Chemical Biology" etc

CONFERENCES – MEETINGS

More than 150 participations in national and International conferences and meetings, with oral or poster presentations

Invited speaker in conferences and meetings in UK, Singapore, China, Malaysia, Saudi Arabia.

Tenths of invited presentations in National Events (Panhellenic Meeting of Pharmacists, Panhellenic Meeting of Applied Pharmacy, Immunology, Medicinal Chemistry, Biosciences e.t.c.)

Invited Speaker in University of Nicosia, European University of Cyprus

Member of Organizing Committees of tenths of Meetings

FUNDING – PROJECTS PARTICIPATION

General Secretariat for Research

Thales: «Autoimmunity»

2012 – 2015, 600000 Euros, Coordinator (Collaboration with Medical Schools of Athens and Larisa)

Hellas - Turkey: «MuSK Myasthenia gravis»

2011 – 2013, 15000 Euros, Coordinator

PEP W. Greece «Innovation in Therapeutics»

2006-2008, 900000 € (In collaboration with S. Tzartos, P. Kordopatis, A. Papapetropoulos and G. Sproulias)

PENED 2003 «Studies of extracellular domains of acetylcholine receptor 2005-2008, 120000 € (In collaboration with S. Tzartos, PI)

e-learning: Research and development of a prototype distance learning system for biosciences”
2004-2006 65000 € (In collaboration with S. Tzartos, PI)

Ministry of education

«PITHAGORAS» Structural studies of recombinant extracellular domains of AChR

2004-2006 65.000 € (In collaboration with S. Tzartos and G. Spyroulias)

Ministry of Employment

EQUAL II: Development of a distance learning platform for people suffering from myasthenia gravis

2005 – 2007 170000 € (Scientific Responsible)

University of Patras

Project «Karatheodoris»: Structural studies of AChR

2005 - 2007 25000 € (Scientific Responsible)

HPV Patras (Network) Principal Investigator

Other

MDA-Hellas. Myasthenia gravis studies
European Union

FP7 Researchers' Night 2007 - 2017

The Greek events, Σύνολο Total funding ~ 180000 (PI)

LLP Leonardo: Wings2Fly: Innovative interventions for disadvantaged
2007-2008 18.000 € Principal Investigator

Other

FP7, REGPOT – SEE-DRUG, Coinvestigator (PI: G. Spyroulias)
2012 – 2014

Private Funding

NOBACCO. 2014 – Today. 15000

AQUARIUS PROJECT.. 2015 – Today. 200000

E-cig Hellas. 2016 – Today. 15000

PATENTS

1. **Improvement in crystallisation and crystal growth (EPO and US PATENT OFFICE) October 2012**
2. **Controlling cell cultures by wireless microcurrent stimulation, OVI, April 2013**
3. **Method for increasing cheese production, OVI May 2017**
4. **Method for reducing alcohol concentration in an alcoholic solution, OVI September 2017**

ADMINISTRATION

Member of Patras University Senate for two years, 2007-2008 and 2009-2010

Head of Laboratory of Molecular Biology and Immunology, Department of Pharmacy, University of Patras, for 4 years

Director of BIOHealth Hub, Patras Science Park (9/2016)

Responsible for the ECTS programme, Department of Pharmacy, University of Patras, for 4 years (2007 –)